Poster discussion presentation ... titled "Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its affinity for HIV gp41 IgM antibodies”
Richmond, BC (PRWEB) July 07, 2015
bioLytical Laboratories Inc. announced today that its abstract highlighting early HIV detection using INSTI HIV-1/HIV-2 Antibody Test was accepted for presentation at the 8th Annual International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver. The results will be presented Wednesday, July 22nd from 1:00 pm to 2:00pm Pacific Standard Time at the poster discussion on Novel Programmatic Approaches for Diagnostics.
bioLytical is pleased to be selected by IAS from many reputable abstract submissions and is looking forward to showcasing its new data at this internationally renowned conference. The conference will provide new insights into HIV disease development, prevention and treatment where approximately 6,000 delegates from across the globe will be in attendance.
The treatment as prevention (TasP) strategy established by Vancouver-based researcher, Dr. Julio Montaner, was first adopted by healthcare agencies in British Columbia (B.C.) and has shown impressive results that have rippled through the global HIV/AIDS community. By 2012, B.C.’s rate of new HIV diagnoses had decreased to their lowest point ever. With the recent adoption by the United Nations of the TasP strategy and the ambitious 90-90-90 target, Vancouver has become the perfect back drop to showcase innovations to the global scientific community.
“INSTI HIV-1/HIV-2 Antibody Test has been a recommended tool for HIV detection in all healthcare settings due to its quick, accurate results. Previously, studies have proven INSTI’s performance in early detection but bioLytical’s scientists have replicated and pinpointed this connection to IgM. The Company is delighted to have the opportunity to share these findings this month and looks forward to connecting with many key opinion leaders this year at the world-renowned IAS Conference.” said Rick Galli, Chief Technical Officer of bioLytical Laboratories.
In addition, the Company is equally pleased to announce its INSTI HIV-1/HIV-2 Antibody test will also be featured in two separate poster discussions at IAS 2015. The two poster discussion presentations (Abstract #WEPDD0106, Room 118-120 and Abstract #A-729-0097-02698, Room 121-122) titled “Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its affinity for HIV gp41 IgM antibodies” and "Reliability of rapid HIV-1/HIV-2 INSTI on plasma and capillary blood for diagnosis of non B subtypes and circulating recombinant forms of HIV-1 circulating in Gabon,” will be available on the bioLytical website at http://www.biolytical.com following the conference.
About bioLytical Laboratories
bioLytical Laboratories is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point-of-care in vitro medical diagnostics using its proprietary INSTI™ technology platform. Today, the company markets and sells its signature INSTI™ HIV test and has a world-wide footprint of regulatory approvals including U.S. FDA approval, Health Canada approval and CE mark from European regulators. Their product provides a highly accurate HIV test result in as little as 60 seconds translating into a compelling value proposition for patients, healthcare professionals and public health organizations. For more information on bioLytical Laboratories, please visit http://www.biolytical.com.